Albumin solution
Brand names: Human Albumin Solution 4.5%, 20%
Human albumin solution is a plasma-derived colloid used for volume replacement and to maintain plasma oncotic pressure in conditions such as hypovolaemia, hypoalbuminaemia and during therapeutic plasma exchange or large-volume paracentesis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Albumin is the major plasma protein contributing to colloid osmotic pressure; infused albumin expands the intravascular volume by drawing and retaining fluid within the circulation.
Prescribing in practice
- Use cautiously in patients at risk of circulatory overload, including those with cardiac failure or renal impairment, as rapid infusion can precipitate fluid overload and pulmonary oedema.
- Choose the appropriate concentration for the clinical purpose, as isotonic and concentrated preparations have different volume and oncotic effects.
- As a blood-derived product it carries a theoretical infection risk and must be prescribed and administered according to local transfusion and traceability policy.
Monitoring
Monitor blood pressure, fluid balance and signs of circulatory overload during and after infusion, with electrolytes and haemodynamic status as clinically indicated.
Counselling the patient
- This is a product made from human blood plasma given by a drip.
- Report any breathlessness, rash or feeling unwell during the infusion.
- The team will monitor your fluid balance closely.
Evidence & guidelines
Albumin use is informed by evidence such as the SAFE trial and guidance supporting its role in specific indications including spontaneous bacterial peritonitis and large-volume paracentesis.
Reference: BSG cirrhosis 2021; EASL 2018; NICE CG174; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.